The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 268 participants.

Also called NCT05000411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 268 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05000411
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05000411. Randomized; double masking; primary purpose treatment. Start 2021-08-25 (actual); primary completion 2023-08-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling
Intervention (Drug)
Compound Danshen Dropping Pills (CDDP)
Intervention (Drug)
Placebo
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct05000411
Content hash
6b8c965ef1a227d2e00a01bd00ee8a085f8e36027b5642b1badf2e3bbea9147f